Breast |
(Rivera et al., 2006; Trudeau et al., 2006; Lin, 2013) |
Cyclophosphamide, fluorouracil, methotrexate, doxorubicin, capecitabine, temozolomide, etoposide, and platinum agents |
Bevacizumab |
Lapatinib |
|
Lung |
(Chiu et al., 2005; De Braganca et al., 2010; Jamal‐Hanjani and Spicer, 2012; Kim et al., 2009; Wu et al., 2007; Wu et al., 2013) |
Cisplatin, etoposide, topotecan, temozolamide, pemetrexed, patupilone |
Bevacizumab |
Erlotinib, getifinib, crizotinib |
|
Melanoma |
(Azer et al., 2014; Falchook et al., 2012; Long et al., 2012; Margolin et al., 2012; Rochet et al., 2011; van den Brom et al., 2013; Weber et al., 2011) |
Temozolomide, fotemustine |
– |
Dabrafenib, vemurafenib |
Ipilimumab, interleukin‐2 |